Univariate and multivariate analysis for PFS
| Univariate analysis . | ||
|---|---|---|
| Variable . | HR (95% CI) . | P value . |
| Year | ||
| 2007-2016 | Reference | N/A |
| 2017-2023 | 1.07 (0.75-1.52) | .72 |
| Sex | ||
| Female | - | N/A |
| Male | 1.19 (0.83-1.69) | .34 |
| Age at auto-HSCT, y | ||
| ≤60 | Reference | N/A |
| >60 | 0.76 (0.48-1.20) | .24 |
| Fracture | ||
| No | Reference | N/A |
| Yes | 0.94 (0.66-1.35) | .75 |
| Bone lesions | ||
| No | Reference | N/A |
| Yes | 1.06 (0.67-1.70) | .79 |
| MM type | ||
| IgGκ | Reference | N/A |
| IgAκ | 0.93 (0.52-1.64) | .79 |
| IgAλ | 2.06 (1.07-3.99) | .03 |
| IgGλ | 1.12 (0.71-1.77) | .63 |
| LCκ | 0.77 (0.46-1.30) | .33 |
| LCλ | 1.49 (0.59-3.74) | .39 |
| Albumin | ||
| ≥3.5 | Reference | N/A |
| <3.5 | 1.50 (1.01-2.21) | .04 |
| B2M | ||
| <3.5 | 0.72 (0.46-1.12) | .14 |
| 3.5 to 5.5 | Reference | N/A |
| >5.5 | 1.06 (0.64-1.77) | .82 |
| LDH | ||
| High | Reference | N/A |
| Normal | 0.67 (0.42-1.06) | .08 |
| ISS | ||
| I | Reference | N/A |
| II | 1.29 (0.85-1.97) | .23 |
| III | 1.48 (0.93-2.35) | .10 |
| R-ISS | ||
| I | Reference | N/A |
| II | 1.52 (0.69-3.37) | .30 |
| III | 2.63 (1.10-6.30) | .03 |
| Lenalidomide pre–auto-HCT | 1.08 (0.72-1.64) | .70 |
| Pre–auto-HCT response | ||
| VGPR or higher | Reference | N/A |
| Less than VGPR | 1.70 (1.20-2.41) | .003 |
| Time from diagnosis to transplant, mo | ||
| >6 | Reference | |
| ≤6 | 1.35 (0.84-2.18) | .21 |
| Post–auto-HCT response | ||
| VGPR or higher | ||
| Less than VGPR | 2.49 (1.59-3.89) | .001 |
| Timing of CR | ||
| CR before HSCT only | Reference | N/A |
| CR before and after HSCT | 0.80 (0.39-1.65) | .55 |
| Multivariate analysis | ||
| Pre–auto-HCT response | ||
| VGPR or higher | Reference | N/A |
| Less than VGPR | 2.30 (1.15-4.63) | .02 |
| R-ISS | ||
| I and II | Reference | N/A |
| III | 2.54 (1.23-5.23) | .01 |
| Univariate analysis . | ||
|---|---|---|
| Variable . | HR (95% CI) . | P value . |
| Year | ||
| 2007-2016 | Reference | N/A |
| 2017-2023 | 1.07 (0.75-1.52) | .72 |
| Sex | ||
| Female | - | N/A |
| Male | 1.19 (0.83-1.69) | .34 |
| Age at auto-HSCT, y | ||
| ≤60 | Reference | N/A |
| >60 | 0.76 (0.48-1.20) | .24 |
| Fracture | ||
| No | Reference | N/A |
| Yes | 0.94 (0.66-1.35) | .75 |
| Bone lesions | ||
| No | Reference | N/A |
| Yes | 1.06 (0.67-1.70) | .79 |
| MM type | ||
| IgGκ | Reference | N/A |
| IgAκ | 0.93 (0.52-1.64) | .79 |
| IgAλ | 2.06 (1.07-3.99) | .03 |
| IgGλ | 1.12 (0.71-1.77) | .63 |
| LCκ | 0.77 (0.46-1.30) | .33 |
| LCλ | 1.49 (0.59-3.74) | .39 |
| Albumin | ||
| ≥3.5 | Reference | N/A |
| <3.5 | 1.50 (1.01-2.21) | .04 |
| B2M | ||
| <3.5 | 0.72 (0.46-1.12) | .14 |
| 3.5 to 5.5 | Reference | N/A |
| >5.5 | 1.06 (0.64-1.77) | .82 |
| LDH | ||
| High | Reference | N/A |
| Normal | 0.67 (0.42-1.06) | .08 |
| ISS | ||
| I | Reference | N/A |
| II | 1.29 (0.85-1.97) | .23 |
| III | 1.48 (0.93-2.35) | .10 |
| R-ISS | ||
| I | Reference | N/A |
| II | 1.52 (0.69-3.37) | .30 |
| III | 2.63 (1.10-6.30) | .03 |
| Lenalidomide pre–auto-HCT | 1.08 (0.72-1.64) | .70 |
| Pre–auto-HCT response | ||
| VGPR or higher | Reference | N/A |
| Less than VGPR | 1.70 (1.20-2.41) | .003 |
| Time from diagnosis to transplant, mo | ||
| >6 | Reference | |
| ≤6 | 1.35 (0.84-2.18) | .21 |
| Post–auto-HCT response | ||
| VGPR or higher | ||
| Less than VGPR | 2.49 (1.59-3.89) | .001 |
| Timing of CR | ||
| CR before HSCT only | Reference | N/A |
| CR before and after HSCT | 0.80 (0.39-1.65) | .55 |
| Multivariate analysis | ||
| Pre–auto-HCT response | ||
| VGPR or higher | Reference | N/A |
| Less than VGPR | 2.30 (1.15-4.63) | .02 |
| R-ISS | ||
| I and II | Reference | N/A |
| III | 2.54 (1.23-5.23) | .01 |
N/A, not available.